Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior

17Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Primary gastric diffuse large B-cell lymphomas may or may not have a concurrent component of mucosa-associated lymphoid tissue lymphoma. Diffuse large B-cell lymphoma/mucosa-associated lymphoid tissue lymphomas are often associated with Helicobacter pylori (H. pylori) infection, suggesting that the large cells are transformed from mucosa-associated lymphoid tissue lymphomas. In contrast, only limited data are available on the clinical and molecular features of pure gastric diffuse large B-cell lymphomas. In 102 pure gastric diffuse large B-cell lymphomas, we found H. pylori infection in 53% of the cases. H. pylori-positive gastric diffuse large B-cell lymphomas were more likely to present at an earlier stage (73% vs 52% at stage I/II, P=0.03), to achieve complete remission (75% vs 43%, P=0.001), and had a better 5-year disease-free survival rate (73% vs 29%, P<0.001) than H. pylori-negative gastric diffuse large B-cell lymphomas. Through genome-wide expression profiles of both miRNAs and mRNAs in nine H. pylori-positive and nine H. pylori-negative gastric diffuse large B-cell lymphomas, we identified inhibition of ZEB1 (zinc-finger E-box-binding homeobox 1) by miR-200 in H. pylori-positive gastric diffuse large B-cell lymphomas. ZEB1, a transcription factor for marginal zone B cells, can suppress BCL6, the master transcription factor for germinal center B cells. In 30 H. pylori-positive and 30 H. pylori-negative gastric diffuse large B-cell lymphomas, we confirmed that H. pylori-positive gastric diffuse large B-cell lymphomas had higher levels of miR-200 by qRT-PCR, and lower levels of ZEB1 and higher levels of BCL6 using immunohistochemistry. As BCL6 is a known predictor of a better prognosis in gastric diffuse large B-cell lymphomas, our data demonstrate that inhibition of ZEB1 by miR-200, with secondary increase in BCL6, is a molecular event that characterizes H. pylori-positive gastric diffuse large B-cell lymphomas with a less aggressive behavior. © 2014 USCAP, Inc..

Figures

References Powered by Scopus

The microRNA.org resource: Targets and expression

2191Citations
N/AReaders
Get full text

Regulatory networks defining EMT during cancer initiation and progression

2161Citations
N/AReaders
Get full text

Direct multiplexed measurement of gene expression with color-coded probe pairs

1711Citations
N/AReaders
Get full text

Cited by Powered by Scopus

EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities

128Citations
N/AReaders
Get full text

Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients

93Citations
N/AReaders
Get full text

Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer

67Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Huang, W. T., Kuo, S. H., Cheng, A. L., & Lin, C. W. (2014). Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior. Modern Pathology, 27(8), 1116–1125. https://doi.org/10.1038/modpathol.2013.229

Readers over time

‘15‘16‘17‘18‘19‘20‘21‘22‘2302468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

75%

Researcher 3

15%

Professor / Associate Prof. 1

5%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

42%

Agricultural and Biological Sciences 6

25%

Biochemistry, Genetics and Molecular Bi... 6

25%

Immunology and Microbiology 2

8%

Save time finding and organizing research with Mendeley

Sign up for free
0